argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
MarketBeat
argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
The study evaluated e
NASDAQ:ARGX